We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Next-Generation DNA Sequencing Refines Pneumonia Diagnosis

By LabMedica International staff writers
Posted on 07 Oct 2014
Applying advanced next-generation sequencing (NGS) of DNA from samples taken from intubated patients with suspected pneumonia has the potential for providing physicians with rapid, precise, culture-independent identification of bacterial, fungal, and viral pathogens and their antimicrobial sensitivity profiles.

Accurate and rapid identification of the microbial pathogens in patients with pulmonary infections could lead to targeted antimicrobial therapy with potentially less adverse effects and lower costs. More...
Toward this end, investigators at George Washington University (Washington DC, USA) combined an NGS approach with data interpretation based on the "PathoScope" bioinformatics software package to analyze bronchial aspirates from 61 intubated patients with suspected pneumonia.

Pathoscope capitalizes on a Bayesian statistical framework that accommodates information on sequence and mapping quality and provides probabilities of matches to a known database of reference genomes. This approach incorporates the possibility that multiple species can be present in the sample or that the target strain is not even contained within the reference database. It also accurately discriminates between very closely related strains of the same species with much less than one time coverage of the genome and without the need for sequence assembly or complex preprocessing of the database or taxonomy. No other method so far described in the literature has been shown to identify species or substrains in such a direct and automatic manner and without the need for large numbers of reads.

The present study used NGS of essentially full-length PCR-amplified 16S ribosomal DNA from the bronchial aspirates. The results from the 61 patients demonstrated that sufficient DNA could be obtained from 72% of samples, 44% of which (27 samples) yielded PCR amplimers suitable for NGS. Out of 27 sequenced samples, only 20 had bacterial culture growth, while microbiological and NGS identification of bacteria coincided in 17 (85%) of these samples. Despite the lack of bacterial growth in seven samples that yielded amplimers and were sequenced, the NGS identified a number of bacterial species in these samples.

Overall, a significant diversity of bacterial species was identified from the same genus as the predominant cultured pathogens. The number of NGS-identifiable bacterial genera was consistently higher than identified by standard microbiological methods.

“Currently, patients who develop pneumonia after entering the ICU are subjected to broad-spectrum antibiotics, which adds costs, potentially increases the risk of development of antimicrobial resistance, and creates a greater likelihood of an adverse effect attributable to the antibiotics,” said senior author Dr. Gary Simon, professor of medicine at George Washington University. “In our paper, we show these methods could improve if we establish a more precise microbiologic cause.”

The study was published in the August 20, 2014, online edition of the Journal of Clinical Microbiology.

Related Links:

George Washington University



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.